Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer

BACKGROUND: Trastuzumab-containing chemotherapy is the first-line treatment for advanced gastric cancer (GC) with HER2 positive. Although PD-1 inhibitors significantly improved the outcome of GC patient’s refractory to previous chemotherapy regimens, few studies explore the role of anti-PD-1 therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yan, Lu, Linbin, Liu, Huan, Chen, Di, Han, Ning, Yao, Ruirong, Wang, Xinlin, Gao, Xianchun, Yu, Jun, Chen, Ling, Zhou, Fenli, Hao, Guangjun, Lu, Yuanyuan, Li, Mengbin, He, Guangbin, Kang, Fei, Li, Zengshan, Tang, Yongqiang, Zhang, Jinsong, Wei, Lichun, Nie, Yongzhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639782/
https://www.ncbi.nlm.nih.gov/pubmed/36353623
http://dx.doi.org/10.3389/fimmu.2022.1003859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639782/
https://www.ncbi.nlm.nih.gov/pubmed/36353623
http://dx.doi.org/10.3389/fimmu.2022.1003859

Ejemplares similares